EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> F-star named Darlene Deptula-Hicks as CFO. The appointment of a U.S.-based financial chief with experience at publicly traded biotechs comes as F-star increases its focus on internal assets. Release 

> BioNTech and Genmab began a first-in-human trial of a PD-L1x4-1BB bispecific in solid tumors. Statement  

> CyTuVax posted data from a phase 2 trial of hepatitis B vaccine HBAI20. The Dutch biotech thinks HBAI20 may work in non-responders to existing vaccines. Release  

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Oncopeptides presented phase 2 data on melflufen in multiple myeloma. Analysts at Jefferies said the response rate underscored the potential of the peptide-conjugated alkylator. Release  

> Oryzon posted dose-finding results from a phase 2 trial of Iadademstat in acute myeloid leukemia. Four-fifths of participants responded to the drug. Statement  

> Medigene shared an updated interim analysis of its acute myeloid leukemia trial. Two of the five early relapses showed mutational load upon entering the study. Release 

Suggested Articles

VistaGen responded to the failure of the ketamine-line drug by vowing to review all the data before deciding on next steps.

Exicure is set to receive $25 million upfront to apply its spherical nucleic acid technology to two collaborative programs. 

Dewpoint Therapeutics is teaming up with Bayer on new drugs for a pair of neglected fields: heart disease and women’s health.